Herbsland recall
This article was originally published in The Tan Sheet
Executive Summary
All 100-tablet bottles of Ancom Anti-Hypertensive Compound Tablets recalled by Herbsland because they contain several Rx drug ingredients, including reserpine, diazepam, promethiazine, company says Jan. 17. Product is "unapproved new drug" and "poses possible serious health risks including sedation, depression and potentially life-threatening abnormalities of the blood," 1Herbsland press release says, although no adverse events have been reported. Sold through distributors, retail stores in the New York metropolitan area and over the Internet, Ancom tablets are labeled for anti-hypertensive use and come in white plastic bottles with an outer cardboard holding carton. Manufacturer is listed as Chinese firm Shanghai Pharmaceutical Industry...
You may also be interested in...
Ancom recall
Availability of Ancom Anti-Hypertensive Compound Tablets has caused one adverse event so far, FDA says March 17. Tai Chien is recalling all 100-count bottles of the product because they contain several Rx ingredients, including diazepam, promethiazine, reserpine, which may pose health risks such as "sedation, depression and potentially life-threatening abnormalities of the blood," agency notes. Herbsland recalled same product in January (1"The Tan Sheet" Jan. 20, 2003, p. 8). Tablets are manufactured by Shanghai Pharmaceutical, sold at retail stories in New York City, online...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.